Flavonoids as Promising Neuroprotectants and Their Therapeutic Potential against Alzheimer's Disease

Alzheimer's disease (AD) is one of the serious and progressive neurodegenerative disorders in the elderly worldwide. Various genetic, environmental, and lifestyle factors are associated with its pathogenesis that affect neuronal cells to degenerate over the period of time. AD is characterized by cognitive dysfunctions, behavioural disability, and psychological impairments due to the accumulation of amyloid beta (Aβ) peptides and neurofibrillary tangles (NFT). Several research reports have shown that flavonoids are the polyphenolic compounds that significantly improve cognitive functions and inhibit or delay the amyloid beta aggregation or NFT formation in AD. Current research has uncovered that dietary use of flavonoid-rich food sources essentially increases intellectual abilities and postpones or hinders the senescence cycle and related neurodegenerative problems including AD. During AD pathogenesis, multiple signalling pathways are involved and to target a single pathway may relieve the symptoms but not provides the permanent cure. Flavonoids communicate with different signalling pathways and adjust their activities, accordingly prompting valuable neuroprotective impacts. Flavonoids likewise hamper the movement of obsessive indications of neurodegenerative disorders by hindering neuronal apoptosis incited by neurotoxic substances. In this short review, we briefly discussed about the classification of flavonoids and their neuroprotective properties that could be used as a potential source for the treatment of AD. In this review, we also highlight the structural features of flavonoids, their beneficial roles in human health, and significance in plants as well as their microbial production.


Introduction
AD is one of the most prevalent neurodegenerative disorders that affects millions of people all over the world [1]. The social and economic burden of AD is high and the number of cases is rising dramatically and may reach to 88 million by 2050 [2]. AD is attributed by several pathological manifestations including profound oxidative stress, synaptic connection loss, cumulative emergence of intracellular tau pathology, accumulation of extracellular amyloid beta (Aβ) plaques, and other aspects [3]. During the onset and progression of AD, various neurological dysfunctions take place that ultimately leads to loss of memory and cognitive deficits that cause interference in daily life of the individuals [4]. Plenty of significant resources have been exhausted to date in its treatment, but the overall results are still disappointing and challenging. AD occures due to disturbance of multiple pathway, therefore, the multi-target approche thruogh hole plant extract will be more promising among the possible therapies. Ongoing analyses have demonstrated that consumption of flavonoid-rich diet can actually improve mental health and cognitive ability in people [5][6][7][8]. Furthermore, several flavonoids have been accounted to limit the progression of AD, and this has been originating from their capacity to improve cognitive function in various preclinical models [8]. The flavonoid-rich foods like cocoa, citrus, green tea, and berry can be ascribed to the connections of flavonoids and their metabolites with various subcellular targets [9,10]. Consequently, flavonoids thus exert their neuroprotective effects by maintaining the neuronal quality and prevent the development of AD, involved in cognitive improvement. Overall, this review summarizes the classification, physiochemical properties, hallmarks of AD, and pharmacological effects of flavonoids against the pathogenesis of AD. This review also includes the molecular pathways targeted by flavonoids to prevent the progression of AD and provide a deep understanding in research of flavonoids.
1.1. Flavonoid Overview. A broad and varied range of organic chemicals are produced by plants, the vast majority of which do not appear to be directly involved in growth and development. Historically, these compounds have been referred to as secondary metabolites specially flavonoids. During the last few years, a myriad of studies has ignited the attention of polyphenolic compounds in the treatment of AD because of their possible therapeutic applications [11]. Flavonoids belong to one of the diverse groups of plant polyphenols, and more than 10,000 flavonoids have been extracted to date from natural resources including wines, vegetables, restorative plants, and organic products [12]. Flavonoids have emerged as a promising leading molecule either alone or in association with other compounds for showing the effective plan and improvement as anti-AD drugs [13].

Flavonoids and Neuroprotection.
Their incredible diversity, circulation, availability, and simple detachment have made them a class of potent candidates for AD therapy. Various in vitro as well as in vivo studies have been conducted defining the antioxidant and neuroprotective property of flavonoids. In addition multiple preclinical and clinical studies also reported the role of flavonoids in the prevention and treatment of cognitive dysfunction, learning, and memory deficits [8]. Acute or chronic administration of flavonoids crosses through the blood-brain barrier suggesting that these compounds can feasibly have a direct effect on the brain and hence could be used as a prophylactic agent [14]. Furthermore, natural and synthetic flavonoids have gained substantial attention not only because of their antioxidative, antiinflammatory, and antiamyloidogenic properties [15] but also because of multiple range of pharmacological effects that ameliorate learning and memory in the AD patients [16]. Moreover, most of the flavonoids are accounted for limiting the movement of AD pathologies, suppress the psychological shortfalls, and viably improve psychological capacities in humans [17]. Besides that, a few specialists are engaged in the various periods of clinical preliminaries, but none of the antiamyloid medication is presently clinically accessible. Because of the harmfulness related to the utilization of accessible medications and their restricted restorative viability, the quest for new anti-AD drugs is as yet in progress [18].

Classification of Flavonoids
More than 10000 different flavonoids have been identified to date which have enormous therapeutic potential. Despite having great diversity, the classification of flavonoids has restricted into six groups based on their molecular structure [17]. These groups include flavonols (rutin and quercetin), flavanols (catechin, epicatechin, and epigallocatechin), isoflavones (genistein, daidzein, glycetin, and formanantine), anthocyanidins (cyanidin, malvidine, and delphinidine), flavanones (hesperetin and naringenin), and flavones (apigenin and luteolin) [19]. Among the above mentioned six classes, the flavones are the most common and abundant within the families and genera of the higher plants [20]. Besides that, flavonoids are separated from one another based on contrasts in the condition of oxidation/reduction and aglycon ring design. Moreover, based on the extent of hydroxylation of aglycon, positions of the hydroxyl groups, saturation of pyran ring, and differences in the derivatization of the hydroxyl groups are major differentiating features among the various classes of flavonoids [21].

Distribution of Flavonoids in Nature
Flavonoids are the essential components of the plant cells hence, ubiquitously distributed in green plants [22] ( Table 1). Additionally, they are part of the human diet due to their abundance in vegetables, fruits, seeds, and beverages such as coffee, tea, and red wine, as well as in medicinal herbs [23]. Being ubiquitous in nature, these secondary metabolites have emerged as an indispensable tool in a variety of nutraceutical, pharmaceutical, medicinal, and cosmetic applications and impose benevolent effects on human health [24]. Different dietary source contains different type of flavonoids with a range of conc. Like Capparis

Hallmarks of Alzheimer's Disease
The neuropathological hallmarks of AD include positive lesions such as amyloid plaques, neurofibrillary tangles, and cerebral amyloid angiopathy and negative lesions such as neuronal and synaptic loss [29].

Amyloid Plaques.
Amyloid plaques also named senile plagues mainly composed of Aβ are one of the major hallmarks, and its accumulation leads to pathogenesis of AD [30]. Amyloid precursor protein (APP) is the precursor molecule in the generation of 37 to 49 amino acid residue pep-tide called Aβ with the help of βand γ-secretase enzymes in neurons ( Figure 1) [31]. The sequential cleavage leads to the deposition of two forms of Aβ with 42 or 40 amino acids (Aβ-40 and Aβ-42) and out of which Aβ-42 is more abundant and pathogenic as compared to Aβ-40 due to its insoluble nature [29]. In case of neurological disorders, the imbalance between Aβ formation and its clearance gets disrupted that ultimately leads to the formation of senile plaques [32]. An in vivo study reported that in the case of healthy people, the production rate of Aβ is lower than its clearance rate [33]; however, in the advancement of AD, the proportion of production and clearance gets disrupted in the brain.

Neurofibrillary Tangles.
NFTs are considered to be another major pathological hallmark of AD. The ultraimages of AD brain revealed that NFTs are composed of fibrils of 10 nm in diameter that form pairs with a helical conformation to give 65 nm paired helical filaments [34]. NFTs are found in both degenerated and dying neurons and composed of hyperphosphorylated tau protein ( Figure 1). Tau is a microtubule-associated protein and its phosphorylated form is found in the somatodendritic region of neurons, and any abnormalities in its production lead to the production of NFTs and neuronal death [35]. The accumulation of

Oxidative Medicine and Cellular Longevity
NFTs is associated with neuronal dysfunction; that ultimately leads to dementia in AD patients.

Cerebral Amyloid Angiopathy (CAA)
. CAA has been recognized as one of the morphologic hallmarks of AD, but its presence is also reported in the neurologically healthy brains of elderly patients ( Figure 1) [36]. CAA results from deposition of β-amyloid in cerebral cortex region and the ultraimages of AD brain revealed that CAA is a major cause of pathologies in AD, including loss of smooth muscle cells, haemorrhage, capillary occlusion, and dementia in the elderly [37,38]. We recently provided the first evidence that in a mouse model of CAA, oral administration of taxifolin, a natural bioactive flavonoid, prevented cognitive impairment through pleiotropic beneficial effects [39]. However, how CAA contributes to vascular dysfunction in AD is unclear, and effective treatments for CAA have not been established.

Biochemical Properties of Flavonoids
Flavonoids are of huge interest in numerous nutraceutical, pharmacological, medical, and cosmetic applications; they are a crucial ingredient. This is explained by their ability to control important cellular enzyme functions as well as their antioxidative [40], anti-inflammatory [41,42], antimutagenic [43], and anticarcinogenic capabilities [44][45][46]. According to numerous researches, flavonoids possess bio-logical properties such as antiallergenic, antiviral, antiinflammatory, and vasodilation effects. These flavonoids can be found in a variety of foods, including cereals, tea, red wine, and fruits and vegetables [47]. The antioxidant activity of flavonoids, however, has drawn the greatest attention because of their capacity to both prevent the creation of free radicals and scavenge existing ones. Cellular damage brought on by oxidative stress has been linked to a number of diseases including diabetes, cancer, cardiovascular disease (CVD), neurological disorders, and ageing. Numerous biological molecules are harmed by oxidative stress, and the easy target is proteins and DNA which involved in every biological processes. Numerous researches have examined the ability of flavonoids to function as antioxidants in vitro, and significant structure-activity connections of the antioxidant activity have been identified [25] In the past years, researcher provided the molecular mechanisms of flavonoids to suppress the activities of specific P450 isozymes, in order to prevent carcinogens [48]. Recent research demonstrated that the flavonoids are also work as antiviral (e.g., quercetin, naringin, hesperetin, and catechin) and antibacterial (apigenin, along with quercetin) against the different kinds of infections [49,50]. The effect of flavonoids, especially quercetin, is reported in the modulation of various inflammatory processes and immunological functions [51]. Tannins, stilbenes, curcuminoids, coumarins, lignans, quinones, and other flavonoids have chemopreventive properties as well  Oxidative Medicine and Cellular Longevity as contribute to the induction of apoptosis by arresting the cell cycle, regulating carcinogen metabolism, and controlling ontogenesis expression, according to research by Ren et al. [48,52]. They also mentioned that the flavonoids' potential mechanisms of action in the prevention of cancer include antioxidant activity and scavenging free radicals, modulation of carcinogen metabolism, control of oncogene and tumorsuppressor gene expression in cell proliferation and differentiation, induction of cell cycle arrest and apoptosis, and modulation of enzyme activities in detoxification. There is a lot of knowledge about flavonoids and how they protect the central nervous system, especially when it comes to neurodegenerative diseases brought on by the interaction of oxidative stress, inflammation, and transition metal accumulation. Like flavonols, flavonoids are linked to a decrease in the prevalence of dementia [53][54][55]. Citrus flavanones such hesperidin, hesperetin, and naringenin, according to Hwang et al. [56] and Wróbel-Biedrawa et al. and Silva dos Santos et al. [57,58], may be able to cross the blood-brain barrier and be an effective treatment for neurodegenerative illnesses. It has also been claimed that of flavonoids have antiaging and antidiabetic properties [59,60].

The Interaction of Flavonoids with Multiple Signalling Pathways in Alzheimer's Disease
Various studies have revealed that flavonoids and their metabolites can exert useful actions on neurological processes through interactions with protein kinase and lipid kinase-signalling cascades [61]. These neuronal signalling pathways include nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway ( Figure 2) [62] as well as the protein kinase C (PKC), tyrosine kinase [63], phosphoinositide-3-kinase (PI3K)/Akt [64], and mitogenactivated kinase (MAPK) signalling pathways [16]. MAPKs are found to regulate a variety of cellular processes by converting extracellular signals into intracellular responses [65]. Flavonoids and their metabolites, on the other hand, can selectively interact with MAPK signalling pathways by interacting with MAPK kinases such as MAP kinase 1 (MEK1), MEK2, and membrane receptors ( Figure 2) [66]. These kinases appear to promote the effect of flavonoids on the extracellular signal-regulated kinase (ERK) pathway [67]. Flavonoids have a structural similarity to a number of pharmacological ERK signalling pathway modulators [68]. Activation of the cAMP response element-binding protein (CREB) has also been observed as a result of ERK activation, which can result in upregulation of neuroprotective pathways as well as changes in memory and synaptic plasticity [69]. The nuclear factors erythroid 2-related factor 2 (Nrf2) and hypoxia-inducible factor-1, which act as modulators of PPAR-γ and activate the PGC-1α pathway, can be stabilised by flavonoids [70]. Flavonoids modify these molecular pathways, slowing the development of Alzheimer's disease by reducing oxidative stress, improving mitochondrial dysfunction, lowering insulin resistance, and improving memory impairment [71]. In addition, flavonoids also regulate PI3K/Akt signalling cascade through direct interactions with their adenosine triphosphate (ATP) binding site. In a study, it has been reported that the flavanone hesperetin has been found to cause activation of the Akt/protein kinase B (PKB) signal transduction cascade to provide prosurvival  [72], while the flavonol quercetin was found to modulate the prosurvival Akt/PKB and ERK1/2 signalling cascade by hampering the activity of PI3K (Figure 2) [73]. Furthermore, it appears that cellular responses differ depending on the degree of interaction with downstream kinases or receptors, implying the possibility of structure-dependent signalling pathways.
Autophagy is a key process that is involved in synaptic plasticity and clearance of aggregate prone proteins in neuronal cells and aberrant autophagy plays a crucial role in neurodegenerative disorders [74]. Currently, flavonoids are being executed as a potential therapeutic tool for autophagy signalling involved in neurodegenerative disorders [75]. The group of few researchers reported that high dose of genistein (150 mg/kg/day) triggered the autophagy induction and promoted the degradation of Aβ and hyperphosphorylated tau in a streptozotocin-induced rat model of the sporadic AD [76]. In another study, it was found that resveratrol, a flavonoid, activated the first step of autophagy through AMPK/ mTORC1 pathway to mitigate cognitive impairment in AD mice. Quercetin, the most potent flavonoid, not only cleared the Aβ aggregates but also delayed paralysis via activation of macroautophagy and limit brain damage in vitro and in vivo [77]. An in vitro study in SH-SY5Y neuronal cells revealed that flavonoid, wogonin, not only reduced the secretion of Aβ in the primary cortical astrocytes but also promoted its clearance through mTOR/autophagy signalling pathway [78]. Silibinin, another flavonoid, has also alleviated neuronal damage by inhibiting autophagy in the hippocampus region of the brain [79]. In addition, the combination of quercetin with silibinin and wogonin have been successfully used in preclinical and clinical studies to clear out the amyloid substance via induction of autophagy by ULK1/mTOR pathway [80]. Some studies reported on dietary intake of fla-

Role of Flavonoids in Neuroprotection
Recently, flavonoid derivatives are being used as a neuroprotective agent in several neurodegenerative disorders including AD. The various aspects of flavonoids as a neuroprotectants are as follows.
7.1. Flavonoids as Neuroprotective Agents. Flavonoids exert a multiplicity of neuroprotective effects against neurodegenerative diseases to suppress neuroinflammation and to improve cognitive function (Figure 3) [87][88][89]. Recently, one study from Gu et al. showed antiamyloid property of the flavonoid prepared from the caper leaf and fruit [90]. Another study from the Szwajgier conferred the neuroprotective effect of a flavonoid (Icariin) derived from the Chinese herb Epimedium brevicornum. Szwajgier showed the ability of icariin to decrease both amyloids-β (Aβ) and APP levels and increase neurogenesis in the brain of Tg2576 mice significantly [91]. Another flavonoid baicalein (5,6,7-trihydroxy-2-phenyl-chromen-4-one) extracted from Scutellaria baicalensis, has strong neuroprotective potential and significantly rescues synaptic plasticity and memory deficits in AD mouse model [92]. In addition, baicalein is able to prevent the damage in the hippocampal long-term potentiation (LTP) induced by Aβ and improve cognitive deficit associated with AD. People have also studied the anticholinesterase activity of few flavonoids [93], and as we know, there is increased activity of cholinesterase in case of AD so flavonoid having anticholinesterase activity will be useful to protect the neuronal damage in the hippocampus area of the AD patient.  [94,95]. A variety of studies revealed the low levels of ACh in AD brains and cholinesterase inhibitors not only increase ACh levels but also conduct the transmission of impulse at synaptic junctions [96]. Uriarte-Pueyo and Calvo summarized and represented 128 flavonoids exhibiting AChE-inhibiting activity making flavonoids anti-Alzheimer agents [97]. A myriad of flavonoid has been employed as inhibitors of AChE, but among them, the quercetin was found to be potent inhibitor of AChE [98]. The information in regard to the presently accessible medications demonstrates that utilizing this methodology is the most successful remedy in AD indicative treatment, along these lines smoothing out the inevitable clinical endorsement of four medications [99]. Attributable to the undesirable impacts and restricted adequacy of the presently accessible medications, there is a critical need to grow more protected and compelling medications [100][101][102]. In view of their intensity as AChE inhibitors, they were viewed as promising remedial specialists in the improvement of new enemy of Alzheimer drugs [103,104].

Flavonoids as Cognition Enhancers.
Flavonoids have been shown to reverse cognitive impairments and inhibit the progression of Alzheimer's disease, implying that they may have therapeutic potential [105]. Flavonoid-rich diets including grape juice, cocoa, and blueberry are used as memory enhancers [82,106,107]. In a randomized controlled clinical study, daily ingestion of anthocyanin-rich cherry juice improved fluency, short-term memory, and long-term memory in aged people (70+) with dementia [108]. Administration of quercetin along with daily usage of flavonoidrich fruits increases cognition, memory retention, and recovery of short-and long-term memory loss [109]. Various studies have looked at flavonoids' antiamyloidogenic effects as a potential natural treatment for Alzheimer's disease. Moreover, flavonoids' effectiveness in learning and memory has been documented in a number of studies [110]. However, there are fewer studies on cognition and memory in animal models fed with fruits with high flavonoid-rich diet sources [111], e.g., anthocyanin-rich mulberry extracts corrected the cognitive impairment in mice with accelerated senescence and AD-like neurodegeneration [112]. A metanalysis revealed that dietary flavonoids improved the cognition function and showed its positive effect against AD pathogenesis [7]. Moreover, several recent studies reported on the beneficial effects of anthocyaninenriched extracts or anthocyanin-enriched wheat grain diet on cognitive function in mouse AD models [113][114][115]. In a transgenic AD mouse model, a citrus flavonoid called nobiletin was found to reduce the strain of Aβ and plaques in the hippocampus, thus enhancing memory deficits caused by Aβ [116]. In both human Swedish mutant APP transgenebearing neuron-like cells and primary neurons, the citrus 7 Oxidative Medicine and Cellular Longevity flavonoid luteolin was found to minimise APP processing by amyloidogenic γ-secretase activity and decrease the generation of Aβ. Furthermore, the accumulation of Aβ in the brains of AD mouse models was prevented by administering curcumin or polyphenol-rich grape seed extracts for nine months [117]. However, further research is required to determine which flavonoid structures have potent beneficial properties as well as their underlying mechanisms of action. Three structural features of natural products have been suggested in a recent study to clarify their inhibitory function against Aβ-42 aggregation [118]. The first feature is carboxy acid derivatives of anthraquinonoids or triterpenoids that can form a salt bridge with basic amino acid residues like Lys28 and Lys16 in Aβ-42 trimers or dimers [119]. The second property is that noncatechol-type flavonoids have molecular planarity due to αβ-unsaturated carbonyl groups that can interact with the intermolecular β-sheet region in Aβ-42 aggregates, especially aromatic rings like Phe20 and Phe19 ( Figure 3) [120]. Catechol-type flavonoids can form Michael adducts with the side chains of Lys28 and Lys16 in monomeric Aβ-42 through flavonoid autoxidation, which is the third characteristic [121].
7.4. Flavonoids as Free Radical Scavenger. Flavonoids possess several biochemical properties, but the most important biological role of flavonoids has been reported to have antioxidant and hydrogen-donating capacity [122]. The functional groups associated with the structure are prominently responsible for the antioxidant property of flavonoids. Oxidative stress is generated because of the imbalance between reactive oxygen species (ROS) and antioxidants and one of the important events in any neurodegenerative disorders. Apart from neurodegenerative disorders, oxidative stress has been linked to various other diseases including ischemic injury, cancer, atherosclerosis and inflammation. Oxidative stress and metal toxicity played a crucial role in the pathogenesis of AD [55]. Flavonoids play a crucial role in preventing the adverse effect of ROS by protecting the neurons against oxidative stress and hence suppress neuronal damage and improve cognitive function [20] [123]. Besides flavonoids, its derivatives have been reported to have potential antioxidant and neuroprotective activity in vitro and in vivo [89,[124][125][126][127]. Various studies have suggested that flavonoids exert its action especially in neuroprotection against AD by affecting gene expression and interacting with mitochondria and the intracellular signalling modulation of cascades that control neuronal differentiation, survival, and death [73]. Moreover, being a potent scavenger molecule, flavones exert an important indirect antioxidant activity contributing to the homeostasis of metal chelation, enzymatic activity modulation, and stabilization of membranes through antilipid peroxidation [122,128]. Apart from the antioxidant activity of the flavonoids, these polyphenolic compounds also play very important role in human health and exhibit several other significant properties including antimicrobial, antiviral, and anticancer [129]. Antioxidant mechanism of the flavonoids reduces the free radical load and improves the health status through activation of antioxidant enzyme system that scavenges the reactive oxygen species (ROS) [130].

Demerits of Flavonoids
The wide accessibility of flavonoids and their new expansion in utilization by people has brought up significant issues with respect to the expected harmfulness of these dietary parts [131]. Albeit most of characteristic items are all around endured; nonetheless, flavonoids and related phytochemicals have been appeared to incite neurobehavioural and endocrine-disturbing impacts [132]. It has been stated that the quercetin possesses very low toxicity for humans and doses of approximately 1 mg/adult/per day have been recommended [133]. It has been reported that long-term consumption of quercetin over several years resulted in the formation of tumors in mice [134]. Afterwards, several studies were conducted but no study had reported the carcinogenicity and other ill effects of flavonoids [135]. The collaborations of flavonoids with CYP3A4, the prevalent human hepatic and intestinal CYP liable for processing half of restorative specialists, are exceptionally compelling. The concurrent organization of flavonoids and clinically utilized medications may cause drug-flavonoid interactions by balancing the pharmacokinetics of specific medications [133]. Dosage also seems to be an essential issue. For example, high doses of resveratrol caused various side effects including nausea, diarrhea, and abdominal discomfort [136]. Moreover, some flavonoids such as resveratrol or epigallocatechin-3-gallate are regarded as pan-assayinterference (PAINS) compounds [137]. Their effect on an organism might be nonspecific, including cell membrane perturbations, rather than specific protein binding [138], especially while supraphysiological doses are applied. Very few studies reported on side effect of flavonoids. Early studies reported that flavonoids (quercetin) act as mutagenic and cause toxicity for gene expression [139,140]. Hodnick et al. observed that myricetin and quercetin caused mitochondrial enzyme inhibition, damage endogenous antioxidant, and accelerate oxidative stress [141]. Some flavonoids also inhibit topoisomerase II, although this help to recover the cancer patients, but beside this, it also increases the risk of leukemia. Further studies needed to further validate this result. Flavonoids also found to interfere with thyroid hormone production in infant with autoimmune disease. But no studies reported regarding flavonoids and thyroid production in healthy population. Tons of data present regarding role of flavonoids in treatment of various disease but still very few clinical studies carried out. Beside this, the rate of translation of preclinical to clinical studies is very less.

Future Prospective
During the last decade, flavonoids received much attention and a variety of beneficial effects have been elucidated against a myriad of neurodegenerative disorders. Further research is needed to discover new flavonoids from nature's bounty so that this may replace using synthetic drugs which are harmful to the body. In this context, there is a need of studies and development programmers related to in vivo studies so one can provide a hopeful and safe picture for the destiny. Presently, the consumption of fruit, greens, 8 Oxidative Medicine and Cellular Longevity and drinks containing flavonoids is recommended, although it is too early to make hints on every day flavonoid intakes. Further studies are needed especially well-designed clinical trials to endorse the clinical effectiveness of flavonoids in neurodegeneration so that it might be used as a better prophylactic agent to improve the human health including AD patients. Another issue that needs to be addressed in the flavonoid research is to identify the amount of flavonoids absorbed, either they work in synergistic way or individual in improvement of human health.

Conclusion
This review will provide a brief insight about the pathology of AD and potential of natural flavonoids and their derivatives as active agents against neurological diseases. This should encourage research community in a new direction to exploit such information for the rational design of flavonoid based pharmaceutical drugs for AD. Flavonoid is very vast and present in almost natural sources with range of concentration. Various preclinical/clinical studies reported that flavonoids are effective against various diseases including AD. Further research needed especially clinical studies to standardise the dose, side effect, and bioavailability of flavonoids in AD patients.

Conflicts of Interest
The authors declare no conflict of interest.